The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | GARNET: dostarlimab, a PD-1 antibody in advanced solid tumors
Thierry André, MD, Hospital Saint Antoine, Paris, France, discusses the results of the GARNET study, (NCT02715284), an ongoing Phase I trial evaluating dostarlimab, an anti-PD-1 monoclonal antibody in patients with advanced solid tumors. In this interview, Dr Andre outlines how dostarlimab has demonstrated durable antitumor activity in a cohort of mismatch repair-deficient solid tumor patients, the majority of whom had a gastrointestinal malignancy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
